Guideline
Breast Cancer Screening with Recommendations
Patients with a known genetic predisposition to breast cancer
Known Carrier of a BRCA1 or BRCA2 Mutation (High Penetrance Breast Cancer Predisposing Genes)
- Untested individual with known close relative with BRCA1 or BRCA2 mutation
- Known carrier or untested individual with known close relative with another hereditary breast cancer syndrome gene (Li-Fraumeni syndrome, Cowden’s disease, Peutz-Jeghers syndrome, hereditary diffuse gastric cancer, other)
Recommendations
- Beginning at age 25, CBE at least once per year
- Annual mammogram and MRI beginning at age 25 or individualized based on earliest age onset in family. Preliminary data suggest that alternating MRI and mammography every six months may be helpful.
- If close relative, consider genetic testing
Patients without a known genetic predisposition to breast cancer
Patients Who Should Consider Genetic Testing
- Personal history of breast cancer diagnosed at age ≤ 50
- Personal history of ovarian cancer at any age
- Male relative with breast cancer
- 1st- or 2nd-degree relative diagnosed with breast cancer at < age 50
- 1st-degree relative, or (paternal) 2nd-degree relative diagnosed with DCIS at age ≤ 40 or ovarian cancer (any age)
- A diagnosis of breast cancer (or DCIS) and ovarian cancer in a single 1st- or 2nd-degree relative—or two close relatives in the same lineage
- Two relatives in the same lineage with early onset breast cancer
- Women of Ashkenazi Jewish ancestry may be included despite fewer affected relatives or later age onset
- For women whose genetic test results are positive, follow the
recommendations above - For women whose genetic test results are negative:
- Women in a family with a known mutation who test negative are true
negative and should follow the recommendations for patients at usual risk (below). - Women in a family without a known mutation who test negative should
be referred to a genetics center. If possible, genetic testing should be
performed with a genetic counselor or genetics expert. - Consider breast MRI for patients with a lifetime risk of breast cancer >
20% as defined by BRACPRO or other models that are largely dependent
on family history.
- Women in a family with a known mutation who test negative are true
Patients with a higher than usual risk for breast cancer
Therapeutic Thoracic Radiation (e.g. Hodgkins) Age < 30
- Risk from therapeutic radiation is much greater than risk from diagnostic radiation. The risk from infant thymus radiation, fluoroscopy for TB, or multiple X-rays for scoliosis is not well quantified.
Recommendations
- Annual mammogram beginning 8–10 years after radiation or at age 25
- Consider CBE at least once per year beginning at age 25
- Annual MRI in addition to annual mammogram
Histology
- Lobular carcinoma in situ (LCIS)
- History of ductal carcinoma in situ (DCIS)
- History of invasive breast cancer
- Atypical ductal or lobular hyperplasia (ADH or ALH): consider using the Gail Model for risk assessment
Recommendations
- Annual mammogram after diagnosis
- CBE at least once per year
- Consider referral to high-risk counseling or risk reducing medication
Reproductive and Other Risk Factors
- Menarche before age 12
- Nulliparity
- First birth after age 30
- Prior breast biopsy
- >5 years of combined estrogen/progesterone hormone replacement therapy
Recommendations
- For a patient age ≥ 35 with a constellation of these risk factors, consider assessment via the Gail Model to determine her level of risk for breast cancer.
- For patients with Gail Model five-year risk ≥ 1.67: CBE at least once per year, annual mammogram, consider high-risk counseling or risk reducing medication. (USPSTF recommends starting medication at ≥ 3.0. Patient may also be eligible for risk reducing clinical trials.)
Patients with a usual risk for breast cancer
Patients Who Have None of the Risk Factors Listed Above
Recommendations
- Age ≥ 50: Begin bi-annual mammograms, consider annual CBE
- Age 40-49: Annual breast cancer risk discussion with risk factor review and CBE, consider bi-annual mammogram
- Age < 40: Consider CBE every 1–3 years
See Also
More CRICO Guidelines or Algorithms
CRICO decision support tools.
General Informed Consent Guidelines
Guideline
A document to assist institutions in reviewing policies, procedures and forms relative to obtaining and documenting informed consent.


Challenge: Take the OB Clinical Guidelines Test
Guideline
Take this test and see if you already follow these best practices from the Obstetrical Services of the CRICO-insured Institutions.

OB Guideline 15: Assessment and Monitoring in Labor and Delivery
Guideline
During prenatal care, the clinician and patient will discuss common events and procedures in labor, including methods of assessing fetal well-being.

Obstetrics Guidelines Listing
Guideline
Easily navigate this web-based version of the OB guidelines 1-35 and the sample form appendices A-H. The OB Guidelines PDF is also available on this page if you want to read or print it in booklet form. (2022 version available)